心电图aVR导联ST段改变对急性心肌梗死患者近期预后价值

目的探讨心电图a VR导联ST段改变对急性心肌梗死(AMI)患者近期预后价值的研究。方法收集我院2012年12月~2015年12月收治的90例首次发生AMI的患者的完整临床资料进行回顾性分析,按照心电图a VR导联ST段是否改变将其分为ST段抬高组和非ST段抬高组,比较2组性别构成比、GRACE危险评分、SYNTAX评分以及预后相关危险因素构成比。结果 90例AMI患者中,ST段抬高组51例,非ST段抬高组39例,2组男女构成比分别为70.6%、29.4%和74.4%、25.6%,差异无统计学意义(P0.05)。而ST段抬高组的GRACE危险评分及SYNTAX评分明显高于非ST段抬高组,差异均有统计学意义(P0.05)。2组预后相关危险因素中,ST段抬高组的AMI病史、吸烟史、糖尿病史、心功能≥3级、高血肌酐构成比均明显高于非ST段抬高组,差异均有统计学意义(P0.05)。结论心电图a VR导联ST段抬高在AMI患者近期预后评估中具有较高价值,并可作为AMI严重病变的重要依据。     

Efficacy and safety of tanezumab administered as a fixed dosing regimen in patients with knee or hip osteoarthritis: a meta-analysis of randomized controlled phase III trials

This study aims to evaluate the efficacy and safety of tanezumab administered as a fixed dosing regimen in patients with knee or hip osteoarthritis. Randomized controlled phase III trials (RCTs) that evaluated the efficacy and safety associated with tanezumab for knee or hip OA were systematically identified by searching electronic databases, including Cochrane Library, PubMed, and Embase, for 30 years from December 1990 up to July 2020. Ten relevant studies were included in our meta-analysis. The research was reported based on the preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines to ensure the reliability and verity of results. Our study showed that the tanezumab groups were more effective than the placebo groups in terms of mean change from the baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain (P < .00001), WOMAC physical functional (P < .00001), and patient’s global assessment (PGA) (P < .00001). Discontinued due to adverse events (AEs) (P < .00001), serious AEs (P = .02), abnormal peripheral sensations (both P < .00001), and peripheral neuropathy (P < .002) in tanezumab groups were significantly higher than that in control groups. Compared with placebo, tanezumab can effectively relieve pain and improve WOMAC physical function and patient’s global assessment (PGA) in knee and hip osteoarthritis. Meanwhile, adverse events are transient in nature and generally well-tolerated. However, we still need large-sample, high-quality studies to investigate the long-term safety of tanezumab to give the conclusion.

     

全降解涂层雷帕霉素药物洗脱冠状动脉支架治疗急性冠脉综合征的疗效及安全性研究

目的 研究全降解涂层雷帕霉素药物洗脱冠状动脉支架(TIVOLI支架)治疗急性冠脉综合征的疗效及安全性.方法 选择我院收治的80例急性冠脉综合征且行冠状动脉造影检查的患者,根据置入支架类型分为TIVOLI组和EXCEL组,并行冠状动脉介入治疗(PCI).跟踪随访6个月,观察两组主要心脏不良事件(MACE)及支架内再狭窄发生情况.结果 两组患者均成功实施PCI治疗并配合临床随访,其中TIVOLI组2例患者随访3个月时因外科手术退出随访,EXCEL组1例患者术后3d心源性死亡退出随访,其余均完成了随访.两组患者MACE的发生率分别为7.5%及5.0%,差异无统计学意义(P＞0.05).结论 TIVOLI支架治疗急性冠脉综合征患者疗效及安全性与EXCEL支架无明显差异.